Bayer (FRA:BAYN)‘s stock had its “neutral” rating reissued by stock analysts at DZ Bank in a report released on Wednesday.
Other equities analysts have also recently issued research reports about the company. Deutsche Bank set a €125.00 ($145.35) price objective on Bayer and gave the company a “buy” rating in a report on Friday, November 30th. Kepler Capital Markets set a €84.00 ($97.67) price target on Bayer and gave the stock a “buy” rating in a report on Friday, November 30th. Warburg Research set a €88.50 ($102.91) price target on Bayer and gave the stock a “buy” rating in a report on Friday, November 30th. Sanford C. Bernstein set a €88.00 ($102.33) price target on Bayer and gave the stock a “buy” rating in a report on Thursday, November 29th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Bayer in a report on Thursday, November 29th. Eight investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Bayer presently has an average rating of “Buy” and a consensus price target of €88.67 ($103.11).
Shares of FRA BAYN opened at €60.82 ($70.72) on Wednesday. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.